Shifting the view of prostate cancer from "androgen-driven" to "androgen receptor-driven" provides a new framework. In curative settings, after the androgen receptor is targeted for a defined period, restoring testosterone is seen as logical to improve patient quality of life once the cancer is destroyed.

After years of successfully intensifying hormonal therapy, the focus in prostate cancer is shifting toward de-intensification. Researchers are exploring intermittent therapy for top responders and developing non-hormonal approaches like radioligands to spare patients the chronic, life-altering side effects of permanent castration.

The term "palliative care" often carries a negative connotation of giving up, causing patient resistance. Framing it as "supportive care" better emphasizes its role in managing symptoms to help patients tolerate cancer treatment longer and improve outcomes.

The term "hormone resistance" was misleading. Researchers discovered that even in a castrate state, prostate cancer tumors produce their own testosterone locally. This maintained androgen receptor signaling, proving the disease was still "androgen addicted" and opening the door for new targeted therapies.

New guidelines from an international working group are replacing patient-insensitive terms like "castration-resistant" with "Androgen Pathway Modulator (APM) resistant/naive." This modernizes language to encompass a broader range of therapies and improve patient communication, while also incorporating sensitive imaging like PSMA PET.

The term "APMR" (Androgen Pathway Modulator Resistant) is being adopted over "CRPC." This new terminology is more scientifically accurate for modern hormonal therapies and uses more patient-friendly language by removing the anxiety-inducing word "castration."

PCWG4 replaces terms like "castration-resistant" with "Androgen Pathway Modulation (APM) resistant." This change is driven by patient feedback finding the term "castration" insensitive and by the need for language that reflects modern treatments that don't always involve medical or surgical castration.

The field is moving away from distressing terms like 'castration-sensitive/resistant' toward a more precise, patient-friendly nomenclature. The new terms—APM-Naive (APMN), APM-Sensitive (APMS), and APM-Resistant (APMR)—better reflect a patient's treatment history within the modern therapeutic landscape.

The standard of care for metastatic castration-sensitive prostate cancer has evolved. ADT plus an ARPI is now the baseline treatment for nearly every patient. Referring to it as 'intensification' is outdated and misrepresents its role as the new standard.